Clinical Trials
3 trialsNCT07574541 2026-06-05
Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT06765902 2026-05-05
Immunotherapy Before and After Surgery
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06765954 2026-05-05
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Phase 2 Withdrawn